Persistent of Inhibitors of interleukin-23 (anti-IL-23) for the treatment of moderate-to-severe psoriasis (msPs) in the routine clinical practice conditions.

Domínguez Senín L., Camacho Parreño S., Sánchez Gómez E. Rodríguez Jorge M., Santos Rubio MD.
Hospital Universitario Juan Ramón Jiménez, Pharmacy Department. Servicio Andaluz de Salud. Huelva. Spain.

BACKGROUND AND IMPORTANCE

Inhibitors of interleukin-23 (anti-IL-23) have emerged as safe and effective options for the treatment of moderate-to-severe psoriasis (msPs).

OBJECTIVES

To evaluate the persistence of anti-IL-23 (guselkumab and risankizumab) in patients with msPs. Secondarily, these patients’ clinical outcomes and health-related quality of life (HRQL) and the safety profile were also assessed.

METHODS

Retrospective observational study from January 2019 to September 2022. Patients with msPs receiving anti-IL-23 were included. Demographic (sex, age) and clinical data (previous biological treatments, therapy duration and baseline Psoriasis Area and Severity Index (PASI)) were collected from the digital medical record. Non-persistence was defined as treatment discontinuation or a treatment gap > 90 days. The cumulative probability of treatment persistence was analysed by Kaplan Meier method. Secondary endpoint: PASI90 response at 1 year, change in HRQL through dermatology life quality index (DLQI) at 1 year, and safety profile.

RESULTS

• 44 patients were included (26 women), with a median age of 53,5 years

\[
\begin{align*}
\text{G:} & \quad 44,8\% \text{ achieved } >4 \text{ points reduction in DLQI score at 1 year. One patient with adverse reaction.} \\
\text{R:} & \quad 71,4\% \text{ achieved } >4 \text{ points reduction in DLQI score at 1 year. Two patient with adverse reaction.}
\end{align*}
\]

Our cohort shows a moderate persistence rate and PASI improvement at 1 year with Gusekumab and a moderate benefit in improving HRQL. High persistence rate and moderate PASI improvement was reached with Risankizumab and a substantial improvement in HQRL. No important adverse reaction were found, without treatment withdrawals.

CONCLUSION